- Findings of a Delphi study suggest there are 3 perceived criteria for what constitutes "cure" in patients with relapsed/refractory Philadelphia-negative (Ph−) B-cell precursor acute lymphoblastic leukemia (ALL).
Why this matters
- Prognosis is poor in this setting, and the concept of "cure" is commonly contested.
- Delphi study among 9 hematologists and 1 hemato-oncologist regarding what constitutes cure in patients with R/R ALL.
- Funding: Amgen Inc.
- The clinicians reached consensus on 3 cure components, which function in a stepwise manner:
- Complete remission: most important in the first 1-3 months as the best early indicator of treatment response.
- Minimal residual disease negativity: most important at 3-6 months of treatment in confirming eradication of malignant cells.
- Prolongation of survival: most important beyond 6 months, assuming the prior 2 outcomes have been realized.
- 80% of the clinicians felt a patient could be considered "cured" at 2 years off therapy; there was high-level consensus that a patient could be considered cured at 3 years off therapy, based on natural history of the disease.
- Limited sample size.
- Some controversy remains surrounding minimal residual disease testing methods and cutoff values for negativity.